|
| |
MedImmuneMedImmune Incorporated is a biotechnology company headquartered in Gaithersburg, Maryland with three products on themarket and a diverse product development portfolio. MedImmune is focused on using advances in immunology and other biological sciences to develop important new products that address significant medical needs in areas such as infectious diseases, transplantation medicine, autoimmune diseases and cancer. In 1998, the Company launched Synagis (palivizumab) in the United States for preventing respiratory syncytial virus (RSV) in high-risk pediatric patients. Synagis is the first monoclonal antibody approved for an infectious disease and has become an important new pediatric product for the prevention of RSV, the leading cause of pneumonia and bronchiolitis in infants and children. The Company also markets CytoGam (Cytomegalovirus Immune Globulin Intravenous (Human), CMV-IGIV) and RespiGam (Respiratory Syncytial Virus
Immune Globulin Intravenous (Human), RSV-IGIV) and has five new product candidates undergoing clinical trials.
| Contact Details: |
| One MedImmune Way |
| Gaithersburg |
| MD |
| 20878 |
| United States of America |
| Tel: | (301) 398-0000 |
| Fax: | 301 527 4200 |
| Email: | infobusdev@medimmune.com |
| WWW: | www.MedImmune.com/
|
|
Loading...
|
Recent Publications by MedImmune: |  |
Increased vagal airway tone in fatal asthma.
Slow-onset asthma deaths are characterized by eosinophilic airway... | 13th November, 2009
| MedImmune, LLC, Clinical Development, One MedImmune Way, Office # 45C20,
| Med Hypotheses. 2009 Nov 9.
DOI Direct Link |
Concomitant administration of seasonal trivalent and pandemic monovalent H1N1 live attenuated influenza vaccines.
Slow-onset asthma deaths are characterized by eosinophilic airway... | 12th November, 2009
| MedImmune, Gaithersburg, MD, and Mountain View, CA, USA.
| Influenza Other Respi Viruses. 2009 Nov;3(6):257-9.
DOI Direct Link |
Antibody-dependent cell-mediated cytotoxicity effector-enhanced EphA2 agonist monoclonal antibody demonstrates potent activity against human tumors.
EphA2 is a receptor tyrosine kinase that has been shown to be... | 6th November, 2009
| MedImmune, Inc., Gaithersburg, MD 20878, USA.
| Neoplasia. 2009 Jun;11(6):509-17, 2 p following 517.
|
Genetic diversity and evolution of human metapneumovirus fusion protein over twenty years.
BACKGROUND: Human metapneumovirus (HMPV) is an important cause of acute... | 5th November, 2009
| Department of Pediatrics, Vanderbilt University School of Medicine,
| Virol J. 2009 Sep 9;6:138.
DOI Direct Link |
The impact of continuous renal replacement therapy on drug therapy.
Critically ill patients with multisystem organ failure often require daily... | 5th November, 2009
| Medical Information, MedImmune, Inc., Frederick, Maryland, USA.
| Clin Pharmacol Ther. 2009 Nov;86(5):562-5. Epub 2009 Sep 2.
DOI Direct Link |
→View more MedImmune research publications. |
Press Releases on MedImmune:
|
 |
| MedImmune Announces Winners of the 4th Respiratory, Immunology and Autoimmunity Research Abstract Competition |
16th November, 2009 |
MedImmune |
GAITHERSBURG, Md., Nov. 16 /PRNewswire/ -- MedImmune today announced the winners of a research abstract competition highlighting the work of the next generation of scientific leaders in respiratory
|
| New Options for Treatment of RA and Lupus are Focus of Rheumatology Thought Leader Panel |
6th November, 2009 |
MedPredict |
-- Role of other mechanisms, including CTLA4, IL-6, IL-17, JAK, Syk,
TNF/PDE4, BTK, MEK, and S1P.
Companies/Partnerships mentioned in this report include: Abbott, Alder, Amgen/Pfizer,
|
| Reportlinker Adds Monoclonal Antibody Therapies 2007: Competitive Landscape and Pipeline Insight |
5th November, 2009 |
Reportlinker |
NEW YORK, Nov. 5 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue.
Monoclonal Antibody Therapies 2007: Competitive Landscape and Pipeline
|
| Zyngenia, Inc. Raises $10 Million in Series A Funding |
4th November, 2009 |
Zyngenia, Inc. |
ROCKVILLE, Md., Nov. 4 /PRNewswire/ -- Zyngenia, Inc., a privately held biotherapeutics company focused on next-generation antibody drug development, today announced that it has secured $10 million
|
| Reportlinker Adds Opportunity Analysis of H1N1 (swine flu) Vaccination Market |
3rd November, 2009 |
Reportlinker |
NEW YORK, Nov. 3 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue.
Opportunity Analysis of H1N1 (swine flu) Vaccination Market
http://www
|
BioPortfolio Ltd provides targeted e-mail address lists for the life science sector - we can enable you to contact around 39 individuals from MedImmune using this service.  Contact BioPortfolio for a quote for a customised Excel verision of BioCorporate or BioEmail databases.
This page has been viewed 1456 times since April 2007, the link to the organisation's website has been followed 209 times Recent Search Terms used to find this page: medimmune publications | patent No. Motavizumab | patent Motavizumab | 2009 medimmune HAI | medimmune inc cytogam EBV antibody | medimmune usa | medimmune usa | medimmune usa | medimmune h1n1 patent | Zyngenia 301 | . Search for more companies in Gaithersburg Search for more companies in MD This site uses Thumbshots previews, resources from the NCBI applied. Maps are centred on zip/postcodes and should not be relied upon for exact building locations. Some information on this page has been collected automatically and may not have been verified.BioPortfolio search results for MedImmune |
